文献速递外周动脉疾病

Absorb依维莫司洗脱生物可吸收血管支架治疗外周动脉疾病的疗效与安全性:单臂Meta分析

Efficacy and Safety of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Peripheral Artery Disease: A Single-Arm Meta-Analysis.
PubMed 文献 · J Endovasc Ther · 2022-05-05

本研究通过检索PubMed、Embase和Cochrane图书馆,纳入4项研究共155例外周动脉疾病患者,分析Absorb依维莫司洗脱生物可吸收血管支架的疗效与安全性。汇总结果显示总体一期通畅率90%、免于靶病变血运重建96%、症状缓解94%、伤口愈合86%,围手术期并发症4%、全因死亡率9%。作者认为该支架安全且通畅率和靶病变血运重建方面临床结局良好,尤其适用于膝下病变伴严重钙化,但结论仍需更多设计更严谨、样本量更大的研究验证。

要点

  • 汇总一期通畅率90%、免于靶病变血运重建96%、症状缓解94%、伤口愈合86%。
  • 围手术期并发症4%,全因死亡率9%。
  • 作者认为该支架安全且临床结局良好,尤其膝下严重钙化病变,但结论需更多研究验证。

核心结论

  • 高血压、高脂血症和糖尿病是外周动脉疾病患者最常见的合并症。
  • Absorb依维莫司洗脱生物可吸收血管支架安全,在通畅率和靶病变血运重建方面显示出良好的临床结局,尤其在膝下病变伴严重钙化时。
  • 该Meta分析的结论仍需更多设计更严谨、执行更严格、样本量更大的相关研究验证。

研究设计与样本

  • 单臂Meta分析,检索PubMed、Embase和Cochrane图书馆的相关研究。
  • 共纳入4项研究,合计155例外周动脉疾病患者。

主要发现

  • 汇总总体一期通畅率为90%,免于靶病变血运重建为96%,症状缓解为94%,伤口愈合为86%。
  • 汇总围手术期并发症为4%,全因死亡率为9%。
  • 术前总闭塞在192处病变中检出43处(22%),平均病变长度为27.26 mm。
  • 合并症汇总比例:高血压65%、高脂血症74%、糖尿病49%、冠心病43%、慢性肾脏病史20%、吸烟57%。

关键数值与推荐

  • 汇总总体一期通畅率90%。
  • 汇总免于靶病变血运重建96%。
  • 汇总症状缓解94%,伤口愈合86%。
  • 汇总围手术期并发症4%,全因死亡率9%。
  • 术前总闭塞43/192处病变(22%),平均病变长度27.26 mm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出该Meta分析的结论仍需更多设计更严谨、执行更严格、样本量更大的相关研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to evaluate the benefits and risks of patients with peripheral artery disease (PAD) treated with Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) by analyzing all the published studies on the clinical characteristics of patients with PAD. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Library were searched for relevant studies. Efficacy, safety, and basic characteristics were analyzed. RESULTS: Four studies were included in meta-analysis, including a total number of 155 patients with PAD. The pooled overall primary patency, freedom from target lesion revascularization (TLR), symptom resolution, and wound healing were 90%, 96%, 94%, and 86%, respectively. The pooled perioperative complication and all-cause mortality were 4% and 9%, respectively. Preoperative total occlusion was detected in 43 of 192 lesions (22%). The mean lesion length was 27.26 mm. In terms of comorbidities, the pooled percentage of hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, chronic kidney disease history, and smoking were 65%, 74%, 49%, 43%, 20%, and 57%, respectively. CONCLUSION: Among these studies, hypertension, hyperlipidemia, and diabetes mellitus were the most common comorbidities in patients with PAD. The Absorb everolimus-eluting BVS was safe and showed the favorable clinical outcomes in both patency and TLR, especially in infrapopliteal disease with heavy calcification. The conclusions of this meta-analysis still needed to be verified by more relevant studies with more careful design, more rigorous execution, and larger sample size.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Fan W, Tan J, Li L, et al. Efficacy and Safety of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Peripheral Artery Disease: A Single-Arm Meta-Analysis. J Endovasc Ther. 2022. PMID: 35510722. doi:10.1177/15266028221091899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。